Philadelphia University + Thomas Jefferson University
Sidney Kimmel Medical College
Department of Dermatology & Cutaneous Biology

Jimenez, Sergio A

< Back



Sergio A. Jimenez, MD

Contact Dr. Jimenez

Bluemle Life Sciences Building, Room 509
233 South Tenth Street
Philadelphia, PA 19107

(215) 503-5042
(215) 923-4649 fax

Medical School

MD Magna Cum Laude, National University of San Marcos, School of Medicine, Lima, Peru - 1964
MS Honoris Cause, University of Pennsylvania, Philadelphia, PA - 1984


Mayo Medical Center, Rochester MN
Philadelphia General Hospital


Hospital of University of Pennsylvania (HUP)

Board Certification

Internal Medicine

Hospital Appointment

Thomas Jefferson University Hospital

Expertise and Research Interests

Dr. Jimenez's research activities have focused on the application of biochemical, molecular biological, and genetic approaches to the study of Scleroderma, fibrotic disorders, and Osteoarthritis. His major contributions have been the identification of mechanisms of cytokine regulation of collagen gene expression and of the interactions between inflammatory cells and fibroblasts, the study of the role of transforming growth factor in tissue fibrosis, the identification of cartilage gene mutations in Osteoarthritis, and the demonstration of microchimeric fetal cells in affected tissues from Scleroderma patients supporting the hypothesis that fetal cell transfer across the placenta during pregnancy may cause the disease.

The goals of Dr. Jimenez's current research interests are to unravel the early events responsible for the initiation of the fibrotic process in systemic sclerosis, focusing on the role of two novel proteins, allograft inflammatory factor-1 and caveolin-1, and to study the role of macrophages as initiators of this process through their interactions with environmental or infectious agents.


Most Recent Peer-Reviewed Publications

  1. Existing and novel biomarkers for precision medicine in systemic sclerosis
  2. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib)
  3. PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis
  4. Update of EULAR recommendations for the treatment of systemic sclerosis
  5. Endothelial cell-specific activation of transforming growth factor-β signaling in mice induces cutaneous, visceral, and microvascular fibrosis
  6. Multiplex assessment of serum cytokine and chemokine levels in idiopathic morphea and vitamin K1-induced morphea
  7. Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis
  8. Exosomes isolated from serum of systemic sclerosis patients display alterations in their content of profibrotic and antifibrotic microRNA and induce a profibrotic phenotype in cultured normal dermal fibroblasts
  9. Human fibrotic diseases: Current challenges in fibrosis research
  10. Stimulation of transforming growth factor-β1-induced endothelial-to-mesenchymal transition and tissue fibrosis by endothelin-1 (ET-1): A novel profibrotic effect of ET-1
  11. Role of muscarinic-3 receptor antibody in systemic sclerosis: Correlation with disease duration and effects of IVIG
  12. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
  13. Severe eosinophilic fasciitis: Comparison of treatment with d-penicillamine plus corticosteroids vs. corticosteroids alone
  14. Treatment of rapidly progressive systemic sclerosis: Current and futures perspectives
  15. Biomarkers in systemic sclerosis
  16. Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue from Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
  17. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: A 10-year longitudinal study from the EUSTAR database
  18. Joint and tendon involvement predict disease progression in systemic sclerosis: A EUSTAR prospective study
  19. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: A EUSTAR prospective study
  20. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- And tissue-specific microRNAs